Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease (Q42542740)

2 November 2017

Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease (English)

1 reference

2 November 2017

0 references

pulmonary hypertension

1 reference

Ivy DD

1

1 reference

2 November 2017

Kinsella JP

series ordinal

2

1 reference

2 November 2017

Ziegler JW

series ordinal

3

1 reference

2 November 2017

Abman SH

series ordinal

4

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

The Journal of Thoracic and Cardiovascular Surgery

2 November 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

2 November 2017

115

1 reference

2 November 2017

4

1 reference

2 November 2017

875-882

1 reference

Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass.

2 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Atrial natriuretic peptide and nitric oxide in children with pulmonary hypertension after surgical repair of congenital heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Inhaled nitric oxide for the adult respiratory distress syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Rebound pulmonary hypertension after inhalation of nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Negative feedback regulation of endothelial cell function by nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Dipyridamole augmentation of response to nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Effective control of refractory pulmonary hypertension after cardiac operations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Inhaled nitric oxide in congenital heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

Inhibition of hypoxic pulmonary vasoconstriction by dipyridamole is not platelet mediated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2898%2970369-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-5223(98)70369-1

1 reference

2 November 2017

1 reference